Current Report Filing (8-k)
January 11 2019 - 7:19AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event
reported):
January 10, 2019
PAVMED
INC.
(Exact Name of Registrant as Specified
in Charter)
Delaware
|
|
001-37685
|
|
47-1214177
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
One
Grand Central Place, 60 E 42
ND
STREET, Suite 4600, New York, New York
|
|
10165
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrants telephone number, including area
code:
(212) 949-4319
N/A
|
(Former Name or Former Address, if Changed Since Last Report)
|
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
[ ]
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
|
|
|
[ ]
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
|
|
|
[ ]
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
|
|
|
[ ]
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [X]
If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item 7.01.
|
Regulation FD Disclosure.
|
Attached as exhibit 99.1
to this Current Report, is a Press Release dated January 10, 2019, issued by PAVmed Inc., a Delaware corporation, (the “Company”),
providing a business update on certain product development initiatives and other corporate matters.
The
information furnished under this Item 7.01 shall not be deemed “filed” for purpose of Section 18 of the
Securities Exchange Act of 1934 nor shall it be deemed incorporated by reference in any disclosure document of the Company,
except as shall be expressly set forth by specific reference in such document.
Item 9.01
|
Financial Statements and Exhibits.
|
SIGNATURE
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Dated:
January 11, 2019
|
PAVMED INC.
|
|
|
|
|
By:
|
/s/
Lishan Aklog .M..D.
|
|
|
Lishan Aklog, M.D.
|
|
|
Chief Executive Officer
|
PAVmed (NASDAQ:PAVM)
Historical Stock Chart
From Mar 2024 to Apr 2024
PAVmed (NASDAQ:PAVM)
Historical Stock Chart
From Apr 2023 to Apr 2024